Response criteria
Showing 1 - 25 of >10,000
Chinese Primary Biliary Cholangitis on Ursodeoxycholic Acid
Recruiting
- Primary Biliary Cholangitis (PBC)
- Ursodeoxycholic Acid
-
Beijing, ChinaCentre of non-infectious liver diseases, Beijing 302 Hospital, B
Aug 27, 2021
Squamous Cell Carcinoma of the Head and Neck Trial in Ann Arbor (Axitinib)
Completed
- Squamous Cell Carcinoma of the Head and Neck
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Apr 9, 2021
Binge Eating Disorder, Obesity Trial in Montpellier (Functional MRI, ADO-BEDS scale, R-CMAS scale)
Completed
- Binge Eating Disorder
- Obesity
- Functional MRI
- +2 more
-
Montpellier, FranceChu Montpellier
May 14, 2021
qSOFA, SIRS, and EWS for In-hospital Mortality in Emergency
Recruiting
- Sepsis
- Septic Shock
- Measurement of qSOFA score
- +4 more
-
Ar Rifā', Southern Governorate, Bahrain
- +7 more
Dec 11, 2021
NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor Trial in Boulogne
Recruiting
- NSCLC Patient in a Metastatic Stage Eligible for First-line Treatment With Immune Checkpoint Inhibitor
- assessment of the predictive value of ctDNA level of the prominent mutant allele variation between baseline and week 6, on response to treatment according to RECIST 1.1 criteria.
-
Boulogne Billancourt, France
- +2 more
Jul 12, 2021
Innate CD8+ T Cells and Evolution of Tyrosine Kinase Inhibitor
Recruiting
- Leukemia
- +3 more
- Phenotyping of total and innate CD8+T cells by flow cytometry
-
Nîmes, Gard, FranceCHU de Nîmes
Jul 19, 2021
Renal Tumor With Metastasis, Response Evaluation Criteria in Solid Tumors Trial in Aarhus
Recruiting
- Renal Neoplasm With Metastasis
- Response Evaluation Criteria in Solid Tumors
-
Aarhus, DenmarkAarhus University Hospital
Apr 22, 2020
Hepatocellular Carcinoma, Perfusion Scanner Trial in Amiens (Scannographic evaluation of the tumor response performed with
Completed
- Hepatocellular Carcinoma
- Perfusion Scanner
- Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib
-
Amiens, Picardie, FranceCHU Amiens Picardie
Jul 17, 2020
Pancreatic Neuroendocrine Tumors: Comparison Between Choi and
Completed
- Pancreatic Neuroendocrine Tumors
-
Santander, Cantabria, Spain
- +9 more
Mar 23, 2020
Poorly Differentiated Malignant Neuroendocrine Carcinoma, Neuroendocrine Carcinoma, Grade 3, Neuroendocrine Carcinoma, Grade 1
Completed
- Poorly Differentiated Malignant Neuroendocrine Carcinoma
- +4 more
- Everolimus (Afinitor®)
-
Berlin, GermanyCharité-Universitätsmedizin, Medizinische Klinik m. S. Hepatolog
Oct 27, 2020
Refractory Peripheral T-Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma Trial in Belgium, France (Brentuximab Vedotin -
Completed
- Refractory Peripheral T-Cell Lymphoma
- Relapsed Peripheral T-Cell Lymphoma
- Brentuximab Vedotin - induction
- +3 more
-
Antwerpen, Belgium
- +38 more
Jan 9, 2023
Waldenstrom Macroglobulinemia Trial in China (Ibrutinib)
Active, not recruiting
- Waldenstrom Macroglobulinemia
-
Changchun, China
- +5 more
Jan 27, 2023
Acute Myeloid Leukemia, Adult Trial in Hangzhou (cladribine + homoharringtonine + cytarabine)
Recruiting
- Acute Myeloid Leukemia, Adult
- cladribine + homoharringtonine + cytarabine
-
Hangzhou, Zhejiang, ChinaThe First Affiliated Hospital, Zhejiang University School of Med
Jun 13, 2023
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial (Nemtabrutinib, Ibrutinib, Acalabrutinib)
Not yet recruiting
- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Nemtabrutinib
- +2 more
- (no location specified)
Nov 22, 2023
Malignant Tumor Trial (Experimental: DaRT seeds)
Not yet recruiting
- Malignant Tumor
- Experimental: DaRT seeds
- (no location specified)
Mar 27, 2023
Relapsed or Refractory DLBCL Trial in Worldwide (MK-2140 (zilovertamab vedotin))
Recruiting
- Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- MK-2140 (zilovertamab vedotin)
-
Orange, California
- +38 more
Aug 12, 2022
Cutaneous T Cell Lymphoma, Fungoides Mycosis Sezary Syndrome Trial in Ann Arbor (Pembrolizumab, Mogamulizumab)
Not yet recruiting
- Cutaneous T Cell Lymphoma
- Fungoides Mycosis Sezary Syndrome
-
Ann Arbor, MichiganUniversity of Michigan Comprehensive Cancer Center
Jul 13, 2023
Breast Cancer, Metastatic Breast Cancer Trial (Trastuzumab-Deruxtecan (T-DXd))
Not yet recruiting
- Breast Cancer
- Metastatic Breast Cancer
- Trastuzumab-Deruxtecan (T-DXd)
- (no location specified)
Sep 20, 2023
Solid Tumor, Cutaneous Squamous Cell Carcinoma, Endometrial Cancer Trial (favezelimab/pembrolizumab, pembrolizumab, lenvatinib)
Not yet recruiting
- Solid Tumor
- +2 more
- favezelimab/pembrolizumab
- +2 more
- (no location specified)
Sep 7, 2023
Cervical Cancer, Stage IIB Trial (Curcumin, Placebo oral tablet)
Withdrawn
- Cervical Cancer, Stage IIB
- Curcumin
- Placebo oral tablet
- (no location specified)
Dec 5, 2022
Teclistamab in Relapsed and Refractory Multiple Myeloma Patients
Recruiting
- Multiple Myeloma
-
Annecy, France
- +19 more
Sep 28, 2023
Colorectal Cancer Trial in China (TQB2618 injection, Penpulimab injection, Anlotinib HCl capsules)
Not yet recruiting
- Colorectal Cancer
- TQB2618 injection
- +2 more
-
Fuyang, Anhui, China
- +14 more
Aug 23, 2023
Relapsed/Refractory Small Cell Lung Cancer Trial in Worldwide (Tarlatamab)
Recruiting
- Relapsed/Refractory Small Cell Lung Cancer
-
Birmingham, Alabama
- +78 more
Jan 18, 2023
Liver Metastases Trial (Diffusing Alpha Radiation Emitters Therapy (DaRT))
Not yet recruiting
- Liver Metastases
- Diffusing Alpha Radiation Emitters Therapy (DaRT)
- (no location specified)
Apr 23, 2023